Management of multiple sclerosis (MS) and neuromyelitis optica (NMO) in women of fertile age must carefully weigh the risk to the fetus against the risk that rebound of disease activity might cause to the mother. Vukusic and Marignier summarize the currently available safety data on disease-modifying drugs for MS and NMO. Moreover, they outline goals for counselling in women with MS or NMO who wish to have children.
- Sandra Vukusic
- Romain Marignier
